None listed
Conditions
Interventions
Drug : The study is scheduled to be conducted on adults aged 19 to less than 85 years with an increased epicardial fat thickness of 5 mm or more on transthoracic echocardiography among heart failure p
Sponsors
Kangbuk Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - = 18 years and 225 pg/ml for patients without AF, OR > 375 pg/ml for patients with AF - Both ambulatory and hospitalized patients - Epicardial adipose tissue (EAT) thickness > 5 mm measured at end-diastole - Signed and dated informed consent
Exclusion criteria
Exclusion criteria: - Patients being treated with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin, ertugliflozin) within the 8 weeks prior to the screening visit. - Impaired renal function, defined as eGFR 180 mmHg or < 90 mmHg - Other conditions that may be responsible for impaired diastolic function such as hypertrophic/restrictive cardiomyopathy, constrictive pericarditis, complex congenital heart disease and etc. - Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy, or transcatheter aortic valve replacement) or CRT within the 90 days after the screening visit. - History of diabetic ketoacidosis - Participation in any interventional clinical trial (with an investigational drug or device) that is not an observational registry within 15 days of the screening visit. - History of hypersensitivity to SGLT2 inhibitors - Indications of liver disease - Type 1 Diabetes Mellitus (T1DM) - Acute genital infection or urinary tract infection - Current history of bladder cancer - For women of child-bearing potential: Current or planned pregnancy or currently lactating - Life expectancy <6 months at the screening visit - Any other condition that in the judgment of the investigator would jeopardize the patient's participation in the study or that may interfere with the interpretation of study data or if the patient is considered unlikely to comply with study procedures, restrictions and requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Epicardial adipose tissue thickness | — |
Secondary
| Measure | Time frame |
|---|---|
| NT-proBNP;Heart failure related health status using the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score;Body weight | — |
Countries
Korea, Republic of
Contacts
Public ContactHyo-In Choi
Kangbuk Samsung Medical Center
Outcome results
None listed